한글목차

당뇨병 치료제 시장 규모는 최근 빠르게 확대하고 있습니다. 2025년 1,700억 6,000만 달러에서 2026년에는 1,881억 9,000만 달러로, CAGR 10.7%로 성장할 것으로 예상됩니다. 지금까지의 성장은 첨단 치료법의 제한적인 보급, 기존 경구용 당뇨병 치료제에 대한 의존도, 예방의료에 대한 인식 부족, 유통 경로의 제약, 제2형 당뇨병의 증가 등의 요인에 기인하는 것으로 보입니다.

당뇨병 치료제 시장 규모는 향후 몇 년간 급속한 성장이 전망됩니다. 2030년에는 2,789억 6,000만 달러에 달하고, CAGR은 10.3%가 될 전망입니다. 예측 기간의 성장 요인으로는 신규 인슐린 유사체 개발, 병용요법 확대, 디지털 당뇨병 관리 도구 도입, 당뇨병 관리를 위한 헬스케어 인프라 확충, 원격의료와 원격 모니터링의 통합 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 전 세계 당뇨병 유병률 증가, GLP-1 수용체 작용제 및 SGLT-2 억제제 채택 확대, 온라인 약국 및 소매 약국 확대, 맞춤형 당뇨병 관리에 대한 관심 증가, 예방의학 및 조기 진단에 대한 인식 제고 등이 있습니다.

비만 유병률의 증가는 향후 몇 년 동안 당뇨병 치료제 시장의 성장을 견인할 것으로 예상됩니다. 비만은 체지방이 과도하게 축적되어 건강 위험을 크게 증가시키며, 제2형 당뇨병 발병의 주요 요인으로 작용하는 것을 말합니다. 비만율 증가는 주로 당분과 지방이 많은 가공식품과 패스트푸드에 대한 의존도 증가에 따른 고칼로리 음식 섭취 증가와 신체활동량 감소로 인한 과도한 체중 증가가 주요 요인으로 작용하고 있습니다. 당뇨병 치료제는 GLP-1 수용체 작용제 등의 치료를 통해 혈당 조절을 개선하고, 식욕 억제 및 위 내용물 배출 지연에 의한 체중 감소를 촉진하여 비만 환자의 전반적인 대사 건강 상태를 개선하고 비만 관리를 돕습니다. 예를 들어, 영국 정부 기관인 건강 개선 및 격차 대책국이 2024년 5월 발표한 보고서에 따르면, 2022년부터 2023년까지 18세 이상 성인의 약 64%가 과체중 또는 비만으로 분류되어 전년도 63.8%에서 증가 추세를 보였다고 합니다. 따라서 비만 유병률의 증가는 당뇨병 치료제 시장의 확대에 기여하고 있습니다.

당뇨병 치료제 시장의 주요 기업들은 제2형 당뇨병 환자의 개별화된 당뇨병 관리를 돕고 혈당 조절을 개선하기 위해 인지행동치료(CBT)와 같은 혁신적인 접근법 개발에 주력하고 있습니다. 인지행동치료(CBT)는 개인이 비건설적인 사고와 행동을 인식하고 수정할 수 있도록 돕는 구조화된 증거에 기반한 심리적 개입입니다. 예를 들어, 2023년 10월 미국 기반의 디지털 치료 기업 Better Therapeutics Inc.는 디지털 당뇨병 치료 애플리케이션 'AspyreRx'를 발표했습니다. 미국 식품의약국(FDA)으로부터 제2형 당뇨병 치료제로 승인받은 AspyreRx는 18세 이상 성인에게 맞춤형 CBT를 제공하여 당뇨병 치료 결과를 개선하는 행동 변화를 촉진합니다. 이전 BT-001로 알려진 AspyreRx는 무작위 대조 시험에서 표준 치료 대비 통계적, 임상적으로 유의미하고 지속적인 A1c 수치 감소를 보였으며, 혈압, 체중, 기분 및 전반적인 삶의 질 개선이 확인되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Diabetes therapeutics encompass the range of medical treatments and interventions used to manage and control diabetes, a condition marked by elevated blood glucose levels resulting from impaired insulin production or utilization. These therapies include medications such as insulin, which is essential for type 1 diabetes and sometimes used in type 2 diabetes, oral drugs like metformin, and newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors that lower blood sugar through different mechanisms.

The main types of drugs in diabetes therapeutics include oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs. Oral anti-diabetic drugs are medications taken by mouth to help reduce blood glucose levels in individuals with diabetes. These therapies are used for both type 1 and type 2 diabetes. The routes of administration include oral, subcutaneous, and intravenous, and the products are distributed through channels such as online pharmacies, hospital pharmacies, and retail pharmacies. They are used across applications including prevention, treatment, and ongoing care.

Tariffs have affected the diabetes therapeutics market by increasing the cost of imported drugs and raw materials, including insulin and novel oral anti-diabetic compounds. Segments such as GLP-1 receptor agonists, SGLT-2 inhibitors, and combination therapies are most impacted, particularly in Asia-Pacific regions including India and China, which are major manufacturing hubs. While tariffs create cost pressures and potential supply chain disruptions, they also encourage local production, incentivize innovation, and can support domestic pharmaceutical development over the long term.

The diabetes therapeutics market research report is one of a series of new reports from The Business Research Company that provides diabetes therapeutics market statistics, including diabetes therapeutics industry global market size, regional shares, competitors with a diabetes therapeutics market share, detailed diabetes therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes therapeutics industry. This diabetes therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetes therapeutics market size has grown rapidly in recent years. It will grow from $170.06 billion in 2025 to $188.19 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to limited availability of advanced therapeutics, reliance on traditional oral anti-diabetic drugs, low awareness of preventive care, constrained distribution channels, growing burden of type 2 diabetes.

The diabetes therapeutics market size is expected to see rapid growth in the next few years. It will grow to $278.96 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to development of novel insulin analogs, expansion of combination therapies, adoption of digital diabetes management tools, increasing healthcare infrastructure for diabetes care, integration of telemedicine and remote monitoring. Major trends in the forecast period include rising prevalence of diabetes globally, increasing adoption of glp-1 receptor agonists and sglt-2 inhibitors, expansion of online and retail pharmacies, growing focus on personalized diabetes management, enhanced awareness of preventive care and early diagnosis.

The rising prevalence of obesity is anticipated to drive the growth of the diabetes therapeutics market in the coming years. Obesity is defined as excessive accumulation of body fat that poses significant health risks and is a key contributor to the development of type 2 diabetes. The increase in obesity rates is largely driven by higher consumption of calorie-dense diets, with more individuals relying on processed and fast foods rich in sugar and fat, combined with reduced physical activity, leading to excessive weight gain. Diabetes therapeutics support obesity management by improving glycemic control and promoting weight reduction through treatments such as GLP-1 receptor agonists, which suppress appetite and slow gastric emptying, thereby enhancing overall metabolic health in obese patients. For instance, in May 2024, according to a report released by the Office for Health Improvement and Disparities, a UK-based government department, during 2022-2023, around 64% of adults aged 18 years and above were classified as overweight or living with obesity, reflecting an increase from 63.8% in the previous year. Therefore, the growing prevalence of obesity is contributing to the expansion of the diabetes therapeutics market.

Major companies operating in the diabetes therapeutics market are concentrating on developing innovative approaches, such as cognitive behavioral therapy (CBT), to support personalized diabetes management and enhance glycemic control among patients with type 2 diabetes. Cognitive behavioral therapy (CBT) is a structured, evidence-based psychological intervention that helps individuals recognize and modify unhelpful thoughts and behaviors. For instance, in October 2023, Better Therapeutics Inc., a US-based digital therapeutics company, introduced AspyreRx, a digital diabetes therapeutic application. AspyreRx, which received authorization from the US Food and Drug Administration for the treatment of type 2 diabetes, delivers personalized CBT to adults aged 18 and older to encourage behavioral changes that improve diabetes outcomes. Previously known as BT-001, AspyreRx demonstrated statistically and clinically meaningful, sustained reductions in A1c levels compared with standard care, along with improvements in blood pressure, body weight, mood, and overall quality of life in a randomized controlled trial.

In June 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Sigilon Therapeutics Inc. for $0.034 billion. Through this acquisition, Eli Lilly aims to reinforce its diabetes care portfolio by advancing innovative cell-based therapies for type 1 diabetes, particularly by further developing Sigilon's SIG-002 program, which focuses on restoring insulin production through encapsulated islet cell replacement and has the potential to reduce daily disease management demands and offer a functional cure. Sigilon Therapeutics Inc. is a US-based biotechnology company specializing in diabetes therapeutics.

Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the diabetes therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetes therapeutics market consists of revenues earned by entities by providing services such as blood sugar monitoring, medication management, insulin therapy support, and lifestyle counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes therapeutics market also includes sales of insulin, oral hypoglycemic agents, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetes Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses diabetes therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetes therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetes therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug: Oral Anti-Diabetic Drugs; Insulin; Non-Insulin Injectable Drug; Combination Drug
• 2) By Type: Diabetes 1; Diabetes 2
• 3) By Route Of Administration: Oral; Subcutaneous; Intravenous
• 4) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies
• 5) By Application: Preventive; Treatment Or Care
• Subsegments:
• 1) By Oral Anti-Diabetic Drugs: Biguanides; Sulfonylureas; DPP-4 Inhibitors; SGLT-2 Inhibitors; Thiazolidinediones; Meglitinides; Alpha-Glucosidase Inhibitors
• 2) By Insulin: Rapid-Acting Insulin; Short-Acting Insulin; Intermediate-Acting Insulin; Long-Acting Insulin; Premixed Insulin
• 3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists; Amylin Analogs
• 4) By Combination Drug: Oral Combination Therapies; Oral and Injectable Combination Therapies
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Novartis AG; Sanofi S.A.; AstraZeneca PLC; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Novo Nordisk A/S; Boehringer Ingelheim International GmbH; Biocon Biologics Limited; MannKind Corporation; Lexicon Pharmaceuticals Inc.; Adocia S.A.; Oramed Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Diabetes Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Diabetes Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Diabetes Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Diabetes Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Rising Prevalence Of Diabetes Globally
  • 4.2.2 Increasing Adoption Of Glp-1 Receptor Agonists And Sglt-2 Inhibitors
  • 4.2.3 Expansion Of Online And Retail Pharmacies
  • 4.2.4 Growing Focus On Personalized Diabetes Management
  • 4.2.5 Enhanced Awareness Of Preventive Care And Early Diagnosis

5. Diabetes Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals And Clinics
• 5.2 Pharmacies (Retail And Online)
• 5.3 Diabetes Care Centers
• 5.4 Home Healthcare Providers
• 5.5 Research And Academic Institutions

6. Diabetes Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Diabetes Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Diabetes Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Diabetes Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Diabetes Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Diabetes Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Diabetes Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Diabetes Therapeutics Market Segmentation

• 9.1. Global Diabetes Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug
• 9.2. Global Diabetes Therapeutics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diabetes 1, Diabetes 2
• 9.3. Global Diabetes Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Subcutaneous, Intravenous
• 9.4. Global Diabetes Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
• 9.5. Global Diabetes Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Preventive, Treatment Or Care
• 9.6. Global Diabetes Therapeutics Market, Sub-Segmentation Of Oral Anti-Diabetic Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors
• 9.7. Global Diabetes Therapeutics Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin
• 9.8. Global Diabetes Therapeutics Market, Sub-Segmentation Of Non-Insulin Injectable Drug, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• GLP-1 Receptor Agonists, Amylin Analogs
• 9.9. Global Diabetes Therapeutics Market, Sub-Segmentation Of Combination Drug, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral Combination Therapies, Oral and Injectable Combination Therapies

10. Diabetes Therapeutics Market Regional And Country Analysis

• 10.1. Global Diabetes Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Diabetes Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Diabetes Therapeutics Market

• 11.1. Asia-Pacific Diabetes Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Diabetes Therapeutics Market

• 12.1. China Diabetes Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Diabetes Therapeutics Market

• 13.1. India Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Diabetes Therapeutics Market

• 14.1. Japan Diabetes Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Diabetes Therapeutics Market

• 15.1. Australia Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Diabetes Therapeutics Market

• 16.1. Indonesia Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Diabetes Therapeutics Market

• 17.1. South Korea Diabetes Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Diabetes Therapeutics Market

• 18.1. Taiwan Diabetes Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Diabetes Therapeutics Market

• 19.1. South East Asia Diabetes Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Diabetes Therapeutics Market

• 20.1. Western Europe Diabetes Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Diabetes Therapeutics Market

• 21.1. UK Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Diabetes Therapeutics Market

• 22.1. Germany Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Diabetes Therapeutics Market

• 23.1. France Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Diabetes Therapeutics Market

• 24.1. Italy Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Diabetes Therapeutics Market

• 25.1. Spain Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Diabetes Therapeutics Market

• 26.1. Eastern Europe Diabetes Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Diabetes Therapeutics Market

• 27.1. Russia Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Diabetes Therapeutics Market

• 28.1. North America Diabetes Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Diabetes Therapeutics Market

• 29.1. USA Diabetes Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Diabetes Therapeutics Market

• 30.1. Canada Diabetes Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Diabetes Therapeutics Market

• 31.1. South America Diabetes Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Diabetes Therapeutics Market

• 32.1. Brazil Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Diabetes Therapeutics Market

• 33.1. Middle East Diabetes Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Diabetes Therapeutics Market

• 34.1. Africa Diabetes Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Diabetes Therapeutics Market, Segmentation By Drug, Segmentation By Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Diabetes Therapeutics Market Regulatory and Investment Landscape

36. Diabetes Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Diabetes Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Diabetes Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Diabetes Therapeutics Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

37. Diabetes Therapeutics Market Other Major And Innovative Companies

• Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.

38. Global Diabetes Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Diabetes Therapeutics Market

40. Diabetes Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Diabetes Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Diabetes Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Diabetes Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer